|
|
The contemporary science about drugs consists of two main disciplines - pharmacology and pharmaceutics. The first is responsible for research of medico-biological properties of drugs, the second – for their chemical structure and production techniques investigations. Researches are curried out in one and another directions. Pharmacological studies could be justly considered as one of the priority directions. It is possible to say that in this sphere we touched on the main tasks of this discipline, i.e. we study drug discovery and drug side effects problems. Also we develop drug safety methods and analyze clinical trials data. During our life we have taken a great amount of drugs and bioactive compounds, however far from everyone think about that, besides perceptible benefit, they do irreparable damage to the our organisms. For example, taking widely known aspirin and others salicylates (the matter concerns recommended curative dose, not an overdose) could have pernicious effect on the state of blood and liver. Strange as it may seem, scientists started detailed research of drug side effects comparatively recently and by our sight not in an optimal volume. We should add that Kinetic Modeling have at this point the number of significant advantages in comparison with others methods of Systems Biology. Everything said above concerns also the problem of drug safety, i.e. development of such methods of drug using when the variety of their side effects decreases maximally with keeping of positive medical action. We are focusing our attention on the research in this field of pharmacology as well; that confirms the received results. Model approach, which is developed in the ISBSPb, allows to increase an eficacy of processing and analysis data of the different stages of clinical trials. In the competitive pharmaceutical and biotech landscape, the market success of any new product depends on how well a company executes a clinical development program. Success depends on integrating scientific and clinical data to the development and commercialization of therapies. Exactly for this we have developed in the ISBSPb several innovative techniques for these tasks. |
|||||||||||
|
|||||||||||
|
|||||||||||
|
<< Start < Prev 1 2 3 Next > End >> |
|||||||||||
| Page 1 of 3 | |||||||||||
| 1. | DBSolve Manual (Software/DbSolve Optimum) | 161 |
| 2. | Introduction to systems pharmacology modeling and its possible applications to drug discovery and development (Information materials/Workshops) | 90 |
| 3. | Kirill Peskov "Kinetic modeling of Escherichia coli central carbon metabolism" (Publications/Abstracts of Ph.D. thesises) | 82 |
| 4. | ISBSPb Results and Experience (Information materials/Presentations) | 81 |
| 5. | Материалы к учебному курсу "Моделирование в системной биологии и биомедицине" (Information materials/Workshops) | 38 |
| Учебный курс "Моделирование в системной биологии и биомедицине" Tuesday, 12 April 2011 |
| 28 марта на семинаре ИСБСПб выступит Дмитрий Алексеев Thursday, 03 March 2011 |
| Collection of signatures under young scientists open letter about 94-FZ law Wednesday, 02 March 2011 |
| The ISBSPb conference 2011 Tuesday, 08 February 2011 |
| Oksana Galzitskaya will present lecture at ISBSPb seminar on the 31th of January Wednesday, 26 January 2011 |
| Merry Christmas and Happy New Year!!!! Friday, 31 December 2010 |
| Time and place of the 22th of November seminar has beeen changed Friday, 19 November 2010 |
|
Institute for Systems Biology SPb Moscow, Leninskie Gory, 1, build.75G, office. 613, Science park, 119992 |